iCAD (ICAD) 10-Q 6 Aug 21 2021 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2021	Jul. 30, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Registrant Name	ICAD INC
Entity Central Index Key	0000749660
Current Fiscal Year End Date	--12-31
Document Quarterly Report	true
Document Transition Report	false
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Trading Symbol	ICAD
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Address, State or Province	NH
Entity Shell Company	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		25,035,893
Entity Tax Identification Number	02-0377419
Entity File Number	001-09341
Entity Incorporation, State or Country Code	DE
Entity Address, City or Town	Nashua
Entity Address, Address Line One	98 Spit Brook Road, Suite 100
Entity Address, Postal Zip Code	03062
City Area Code	603
Local Phone Number	882-5200

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 37,889	$ 27,186
Trade accounts receivable, net of allowance for doubtful accounts of $104 in 2021 and $111 in 2020	11,107	10,027
Inventory, net	2,861	3,144
Prepaid expenses and other current assets	1,742	1,945
Total current assets	53,599	42,302
Property and equipment, net of accumulated depreciation of $6,935 in 2021 and $6,778 in 2020	921	744
Operating lease assets	1,370	1,758
Other assets	1,532	1,527
Intangible assets, net of accumulated amortization of $8,610 in 2021 and $8,494 in 2020	777	889
Goodwill	8,362	8,362
Total assets	66,561	55,582
Current liabilities:
Accounts payable	1,039	2,869
Accrued and other expenses	6,606	7,039
Lease payable—current portion	851	726
Deferred revenue	5,964	6,117
Total current liabilities	14,460	16,751
Lease payable, long-term portion	646	1,075
Notes payable, long-term portion		6,960
Deferred revenue, long-term portion	424	267
Deferred tax	4	4
Total liabilities	15,534	25,057
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.01 par value: authorized 1,000,000 shares; none issued
Common stock, $0.01 par value: authorized 30,000,000 shares; issued 25,213,302 as of June 30, 2021 and 23,693,735 as of December 31, 2020 Outstanding 25,027,471 as of June 30, 2021 and 23,508,575 as of December 31, 2020	251	236
Additional paid-in capital	299,049	273,639
Accumulated deficit	(246,858)	(241,935)
Treasury stock at cost, 185,831 shares in 2021 and 2020	(1,415)	(1,415)
Total stockholders' equity	51,027	30,525
Total liabilities and stockholders' equity	$ 66,561	$ 55,582

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Allowance for doubtful accounts on trade accounts receivable	$ 104	$ 111
Property and equipment, accumulated depreciation and amortization	6,935	6,778
Intangible assets, accumulated amortization	$ 8,610	$ 8,494
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	25,213,302	23,693,735
Common stock, shares outstanding	25,027,471	23,508,575
Treasury stock, shares	185,831	185,831

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue:
Total revenue	$ 7,826,000	$ 5,567,000	$ 16,470,000	$ 12,118,000
Cost of revenue:
Amortization and depreciation	79,000	98,000	158,000	195,000
Total cost of revenue	2,288,000	1,210,000	4,643,000	3,251,000
Gross profit	5,538,000	4,357,000	11,827,000	8,867,000
Operating expenses:
Engineering and product development	2,268,000	1,878,000	4,460,000	4,089,000
Marketing and sales	3,429,000	2,631,000	6,853,000	6,239,000
General and administrative	2,652,000	2,110,000	4,803,000	4,642,000
Amortization and depreciation	60,000	49,000	115,000	101,000
Total operating expenses	8,409,000	6,668,000	16,231,000	15,071,000
Loss from operations	(2,871,000)	(2,311,000)	(4,404,000)	(6,204,000)
Interest expense	(28,000)	(115,000)	(140,000)	(245,000)
Other income	5,000	33,000	7,000	75,000
Loss on extinguishment of debt	(386,000)	0	(386,000)	(341,000)
Loss on fair value of convertible debentures				(7,464,000)
Other expense, net	(409,000)	(82,000)	(519,000)	(7,975,000)
Loss before income tax expense	(3,280,000)	(2,393,000)	(4,923,000)	(14,179,000)
Tax expense	0	(5,000)	0	(31,000)
Net loss and comprehensive loss	$ (3,280,000)	$ (2,398,000)	$ (4,923,000)	$ (14,210,000)
Net loss per share:
Basic	$ (0.13)	$ (0.11)	$ (0.20)	$ (0.67)
Diluted	$ (0.13)	$ (0.11)	$ (0.20)	$ (0.67)
Weighted average number of shares used in computing loss per share:
Basic	24,989	22,396	24,462	21,275
Diluted	24,989	22,396	24,462	21,275
Product [Member]
Revenue:
Total revenue	$ 4,552,000	$ 2,888,000	$ 10,109,000	$ 6,683,000
Cost of revenue:
Total cost of revenue	1,377,000	537,000	2,786,000	1,554,000
Service [Member]
Revenue:
Total revenue	3,274,000	2,679,000	6,361,000	5,435,000
Cost of revenue:
Total cost of revenue	$ 832,000	$ 575,000	$ 1,699,000	$ 1,502,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flow from operating activities:
Net loss	$ (4,923)	$ (14,210)
Adjustments to reconcile net loss to net cash used for operating activities:
Amortization	157	154
Depreciation	115	142
Bad debt provision	(3)	119
Stock-based compensation	1,446	2,077
Amortization of debt discount and debt costs	17	53
Loss on extinguishment of debt	386	341
Deferred tax expense		1
Change in fair value of convertible debentures		7,464
Changes in operating assets and liabilities:
Accounts receivable	(924)	3,201
Inventory	284	(737)
Prepaid and other assets	510	(19)
Accounts payable	(1,829)	(569)
Accrued expenses	(736)	(1,650)
Deferred revenue	(77)	60
Total adjustments	(654)	10,637
Net cash used for operating activities	(5,577)	(3,573)
Cash flow from investing activities:
Additions to patents, technology and other		(6)
Additions to property and equipment	(336)	(180)
Net cash used for investing activities	(336)	(186)
Cash flow from financing activities:
Issuance of common stock pursuant to stock option plans	636	100
Issuance of common stock pursuant to Employee Stock Purchase Plan	114
Proceeds from issuance of common stock, net	23,229	12,289
Principal repayment of debt financing	(7,363)	(4,638)
Repayment on line of credit		(2,000)
Proceeds from notes payable		6,957
Debt issuance costs		(37)
Net cash provided by financing activities	16,616	12,671
Increase in cash and equivalents	10,703	8,912
Cash and cash equivalents, beginning of period	27,186	15,313
Cash and cash equivalents, end of period	37,889	24,225
Supplemental disclosure of cash flow information:
Interest paid	$ 92	127
Taxes paid		31
Issuance of common stock upon conversion of debentures		21,164
Right-of-use assets obtained in exchange for new operating lease liabilities		$ 69

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
Beginning Balance at Dec. 31, 2019	$ 5,071	$ 196	$ 230,615	$ (224,325)	$ (1,415)
Beginning Balance, shares at Dec. 31, 2019		19,546,151
Issuance of common stock relative to vesting of restricted stock	(131)		(131)
Issuance of common stock relative to vesting of restricted stock, shares		68,724
Issuance of common stock, net	12,174	$ 16	12,158
Issuance of common stock, net, shares		1,562,500
Issuance of common stock pursuant to stock option plans	232	$ 1	231
Issuance of common stock pursuant to stock option plans, shares		44,966
Issuance of common stock pursuant Employee Stock Purchase Plan	115		115
Issuance of common stock pursuant Employee Stock Purchase Plan, shares		18,465
Issuance of stock upon conversion of Debentures	21,164	$ 18	21,146
Issuance of stock upon conversion of Debentures, shares		1,819,466
Stock-based compensation	2,077		2,077
Net loss	(14,210)			(14,210)
Ending Balance at Jun. 30, 2020	26,492	$ 231	266,211	(238,535)	(1,415)
Ending Balance, shares at Jun. 30, 2020		23,060,272
Beginning Balance at Mar. 31, 2020	15,083	$ 215	252,420	(236,137)	(1,415)
Beginning Balance, shares at Mar. 31, 2020		21,425,916
Issuance of common stock relative to vesting of restricted stock	(131)		(131)
Issuance of common stock relative to vesting of restricted stock, shares		45,224
Issuance of common stock, net	12,174	$ 16	12,158
Issuance of common stock, net, shares		1,562,500
Issuance of common stock pursuant to stock option plans	36		36
Issuance of common stock pursuant to stock option plans, shares		8,167
Issuance of common stock pursuant Employee Stock Purchase Plan	115		115
Issuance of common stock pursuant Employee Stock Purchase Plan, shares		18,465
Stock-based compensation	1,613		1,613
Net loss	(2,398)			(2,398)
Ending Balance at Jun. 30, 2020	26,492	$ 231	266,211	(238,535)	(1,415)
Ending Balance, shares at Jun. 30, 2020		23,060,272
Beginning Balance at Dec. 31, 2020	30,525	$ 236	273,639	(241,935)	(1,415)
Beginning Balance, shares at Dec. 31, 2020		23,694,406
Issuance of common stock relative to vesting of restricted stock, shares		29,166
Issuance of common stock, net	23,229	$ 14	23,215
Issuance of common stock, net, shares		1,393,738
Issuance of common stock pursuant to stock option plans	636	$ 1	635
Issuance of common stock pursuant to stock option plans, shares		83,748
Issuance of common stock pursuant Employee Stock Purchase Plan	114		114
Issuance of common stock pursuant Employee Stock Purchase Plan, shares		12,244
Stock-based compensation	1,446		1,446
Net loss	(4,923)			(4,923)
Ending Balance at Jun. 30, 2021	51,027	$ 251	299,049	(246,858)	(1,415)
Ending Balance, shares at Jun. 30, 2021		25,213,302
Beginning Balance at Mar. 31, 2021	53,364	$ 251	298,106	(243,578)	(1,415)
Beginning Balance, shares at Mar. 31, 2021		25,143,432
Issuance of common stock relative to vesting of restricted stock, shares		9,166
Issuance of common stock, net	365		365
Issuance of common stock, net, shares		54,814
Issuance of common stock pursuant Employee Stock Purchase Plan	67		67
Issuance of common stock pursuant Employee Stock Purchase Plan, shares		5,890
Stock-based compensation	511		511
Net loss	(3,280)			(3,280)
Ending Balance at Jun. 30, 2021	$ 51,027	$ 251	$ 299,049	$ (246,858)	$ (1,415)
Ending Balance, shares at Jun. 30, 2021		25,213,302

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Note 1 – Basis of Presentation and Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements of iCAD, Inc. and its subsidiaries (together “iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of the Company’s management, these unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at June 30, 2021, the results of operations of the Company for the three and six-months six-months six-months Although the Company believes that the disclosures made in these interim financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The accompanying interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K six-months Segments The Company reports the results of two segments: Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of advanced image analysis and workflow products. The Therapy segment consists of radiation therapy (“Axxent”) products. Risk and Uncertainty On March 12, 2020, the World Health Organization declared COVID-19 COVID-19 COVID-19. stay-at-home COVID-19 It is currently not possible to predict the duration of the pandemic or the time needed for economic activity to return to prior levels. The COVID-19 COVID-19 COVID-19 The Company’s results for the quarter ending June 30, 2021 reflect a negative impact from the COVID-19 COVID-19. COVID-19 Although the Company did not experience any material impact to trade accounts receivable losses in the quarter ended June 30, 2021, the Company’s exposure may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 COVID-19 Recently Adopted Accounting Pronouncements There are no significant recently adopted accounting pronouncements. For a full list of the Company’s response to all relevant recent accounting pronouncements, please refer to Note 13 below. Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration which the Company expects to be entitled to receive in exchange for these goods or services and excludes any sales incentives or taxes collected from customers which are subsequently remitted to government authorities. Disaggregation of Revenue The following tables presents the Company’s revenues disaggregated by major good or service line, timing of revenue recognition, and sales channel, reconciled to its reportable segments (in thousands). Three months ended June 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 3,164 $ 2,119 $ 5,283 Service contracts 1,625 371 1,996 Supply and source usage agreements — 529 529 Professional services — 18 18 Other — — — $ 4,789 $ 3,037 $ 7,826 Timing of Revenue Recognition Goods transferred at a point in time $ 3,164 $ 2,136 $ 5,300 Services transferred over time 1,625 901 2,526 $ 4,789 $ 3,037 $ 7,826 Sales Channels Direct sales force $ 3,188 $ 1,252 $ 4,440 OEM partners 1,601 — 1,601 Channel partners — 1,785 1,785 $ 4,789 $ 3,037 $ 7,826 Six months ended June 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 7,325 $ 4,222 $ 11,547 Service contracts 3,183 711 3,894 Supply and source usage agreements — 1,010 1,010 Professional services — 19 19 Other — — — $ 10,508 $ 5,962 $ 16,470 Timing of Revenue Recognition Goods transferred at a point in time $ 7,325 $ 4,240 $ 11,565 Services transferred over time 3,183 1,722 4,905 $ 10,508 $ 5,962 $ 16,470 Sales Channels Direct sales force $ 7,063 $ 1,926 $ 8,989 OEM partners 3,445 — 3,445 Channel partners — 4,036 4,036 $ 10,508 $ 5,962 $ 16,470 Three months ended June 30, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 2,702 $ 575 $ 3,277 Service contracts 1,403 385 1,788 Supply and source usage agreements — 490 490 Professional services — — — Other 12 — 12 $ 4,117 $ 1,450 $ 5,567 Timing of Revenue Recognition Goods transferred at a point in time $ 2,714 $ 605 $ 3,319 Services transferred over time 1,403 845 2,248 $ 4,117 $ 1,450 $ 5,567 Sales Channels Direct sales force $ 2,709 $ 805 $ 3,514 OEM partners 1,408 — 1,408 Channel partners — 645 645 $ 4,117 $ 1,450 $ 5,567 Six months ended June 30, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 5,802 $ 1,921 $ 7,723 Service contracts 2,750 732 3,482 Supply and source usage agreements — 861 861 Professional services — 11 11 Other 41 — 41 $ 8,593 $ 3,525 $ 12,118 Timing of Revenue Recognition Goods transferred at a point in time $ 5,843 $ 1,988 $ 7,831 Services transferred over time 2,750 1,537 4,287 $ 8,593 $ 3,525 $ 12,118 Sales Channels Direct sales force $ 4,881 $ 2,274 $ 7,155 OEM partners 3,712 — 3,712 Channel partners — 1,251 1,251 $ 8,593 $ 3,525 $ 12,118 Products. Service Contracts. non-lease Supply and Source Usage Agreements. These agreements represent a separate performance obligation of the Company. The Company allocates revenue to each performance obligation based on the SSP. Professional Services. Other. Contract Balances Contract liabilities are a component of deferred revenue, current contract assets are a component of prepaid and other assets and non-current non-current Contract balances Contract balances Balance at Balance at June 30, 2021 December 31, 2020 Receivables, which are included in ‘Trade accounts receivable’ $ 11,107 $ 10,027 Current contract assets, which are included in “Prepaid and other assets” 742 481 Non-current 1,478 1,434 Contract liabilities, which are included in “Deferred revenue” 6,388 6,384 Timing of revenue recognition may differ from timing of invoicing of customers. The Company records a receivable when revenue is recognized prior to receipt of cash payment and the Company has the unconditional right to such consideration, or unearned revenue when cash payments are received or due in advance of performance. For multi-year agreements, the Company generally invoices customers annually at the beginning of each annual service period. The Company’s accounts receivable from contracts with customers, net of allowance for doubtful accounts, was $ million and $ million as of June 30, 2021 and December 31, 2020, respectively. The Company records net contract assets or contract liabilities on a contract-by-contract non-current non-current Contract liabilities, or deferred revenue from contracts with customers, is primarily composed of fees related to long-term service arrangements, which are generally invoiced in advance. Deferred revenue also includes payments for installation and training that has not yet been completed and other offerings for which the Company has been paid in advance and earn the revenue when it transfers control of the product or service. The balance of deferred revenue at June 30, 2021 and December 31, 2020 was as follows (in thousands): Contract liabilities June 30, 2021 December 31, 2020 Short term $ 5,964 $ 6,117 Long term 424 267 Total $ 6,388 $ 6,384 Changes in deferred revenue from contracts with customers were as follows (in thousands): Six Months Ended June 30, 2021 Balance at beginning of period $ 6,384 Deferral of revenue 6,393 Recognition of deferred revenue (6,389 ) Balance at end of period $ 6,388 The Company expects to recognize estimated revenues related to performance obligation that are unsatisfied (or partially satisfied) in the amounts of approximately $3.8 million in 2021, $3.0 million in 2022, and $1.2 million each year from 2023 through 2025.

Net Loss per Common Share

Net Loss per Common Share	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Net Loss per Common Share	Note 2 – Net Loss per Common Share The Company’s basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. A summary of the Company’s calculation of net loss per share is as follows (in thousands except per share amounts): Three Months Ended Six Months Ended 2021 2020 2021 2020 Net loss $ (3,280 ) $ (2,398 ) $ (4,923 ) $ (14,210 ) Shares used in the calculation of basic and diluted net loss per share 24,989 22,396 24,462 21,275 Diluted shares used in the calculation of net loss per share 24,989 22,396 24,462 21,275 Net loss per share - basic and diluted $ (0.13 ) $ (0.11 ) $ (0.20 ) $ (0.67 ) The shares of the Company’s common stock issuable upon the exercise of convertible securities, stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive are as follows: As of June 30, 2021 2020 Stock options 2,176,607 2,006,221 Restricted stock 21,613 70,992 Total 2,198,220 2,077,213

Inventory

Inventory	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Inventory	Note 3 – Inventory Inventory is valued at the lower of cost or net realizable value, with cost determined by the first-in, first-out Company June 30, 2021 December 31, 2020 Raw materials $ 1,518 $ 1,538 Work in process 192 76 Finished Goods 1,381 1,774 Inventory Gross 3,091 3,388 Inventory Reserve (230 ) (244 ) Inventory Net $ 2,861 $ 3,144

Financing Arrangements

Financing Arrangements	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Financing Arrangements	Note 4 – Financing Arrangements (a) Loan and Security Agreement – Western Alliance Bank On March 30, 2020, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Western Alliance Bank (the “Bank”) that provided an initial term loan (“Term Loan”) facility of $7.0 million and a $5.0 million revolving line of credit. Interest in arrears on the Term Loan began to be repaid on April 1, 2020 and will continue to be paid on the first of each successive month thereafter until the principal repayment starts. Commencing on the principal repayment date March 1, 2022 and continuing on the first day of each month thereafter, the Company will make equal monthly payments of principal, together with applicable interest in arrears, to the Bank. The interest rate is set at 1% above the Prime Rate, which is defined in the Loan Agreement as the greater of 4.25% or the Prime Rate published in the Money Rates section of the Western Edition of the Wall Street Journal. The Prime Rate as of June 30, 2020 was 3.25%. In connection with the Loan Agreement, the Company incurred approximately $141,000 of closing costs. The closing costs have been deduced from the carrying value of the debt and will be amortized through March 30, 2022, the maturity date of the Term Loan. On April 27, 2021, the Company repaid its obligations in the aggregate amount of $7,354,283 and terminated the Loan Agreement with the Bank, and the Company’s collateral securing the facility was released. The Company accounted for this repayment and retirement as an extinguishment of the Loan Agreement. In addition to the outstanding principal and accrued interest, the Company was required to pay the $122,500 final payment, a termination fee of $50,000 and other closing costs totaling approximately $15,000. The Company also wrote off unamortized original closing costs as of the extinguishment date. The Company recorded a loss on extinguishment of approximately $386,000 related to the repayment and retirement of the Loan Agreement. The loss on extinguishment was composed of approximately $140,000 for a prepayment fee, $122,000 for the unaccrued final payment, $65,000 termination and other fees, and $58,000 for the unamortized and other closing costs from origination of the loan. (b) Loan and Security Agreement – Silicon Valley Bank On August 7, 2017, the Company entered into a Loan and Security Agreement, which was subsequently modified several times through November 1, 2019 (as amended, the “SVB Loan Agreement”), with Silicon Valley Bank that provided an initial term loan facility of On March 30, 2020, the Company elected to repay all outstanding obligations (including accrued interest) and retire the SVB Loan Agreement. The Company accounted for this repayment and retirement as an extinguishment of the SVB Loan Agreement. In addition to the outstanding principal and accrued interest, the Company was required to pay the $510,000 final payment, a termination fee of $114,000 and other costs totaling $10,000. The Company also wrote off unamortized original closing costs as of the extinguishment date. In March 2020 the Company recorded a loss on extinguishment of approximately $341,000 related to the repayment and retirement of the SVB Loan Agreement. The loss on extinguishment was composed of approximately $185,000 for the unaccrued final payment, $114,000 termination fee, and $42,000 of unamortized and other closing costs. (c) Convertible Debentures On December 20, 2018, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain institutional and accredited investors (the “Investors”), including, but not limited to, all directors and executive officers of the Company at the time, pursuant to which the Investors purchased unsecured subordinated convertible debentures (the “Convertible Debentures”) with an aggregate principal amount of approximately $7.0 million in a private placement. On February 21, 2020 (the “Conversion Date”), the conditions permitting a forced conversion were met, and the Company elected to exercise its forced conversion right under the terms of the Convertible Debentures. As a result of this election, all of the outstanding Convertible Debentures were converted, at a conversion price of $4.00 per share, into 1,742,500 shares of the Company’s common stock. In accordance with the make-whole provisions in the Convertible Debentures, the Company also issued an additional 76,966 shares of its common stock. The make-whole amount represented the total interest which would have accrued through the maturity date of the Convertible Debentures, less the amounts previously paid, totaling $697,000. The conversion prices related to the make-whole amount were dependent on whether the Investors were related parties or unrelated third parties. Accounting Considerations and Fair Value Measurements Related to the Convertible Debentures The Company had previously elected to make a one-time, irrevocable As of the December 31, 2019 valuation and the prior measurement dates, the Company utilized a Monte Carlo simulation model to estimate the fair value of the Convertible Debentures. The simulation model was designed to capture the potential settlement features of the Convertible Debentures, in conjunction with simulated changes in the Company’s stock price and the probability of certain events occurring. The simulation utilized 100,000 trials or simulations to determine the estimated fair value. The simulation utilized the assumptions that if the Company was able to exercise its forced conversion right (if the requirements to do so were met), that it would do so in 100% of such scenarios. Additionally, if an event of default occurred during the simulated trial (based on the Company’s probability of default), the Investors would opt to redeem the Convertible Debentures in 100% of such scenarios. If neither event occurred during a simulated trial, the simulation assumed that the Investor would hold the Convertible Debentures until the maturity date. The value of the cash flows associated with each potential settlement were discounted to present value in each trial based on either the risk-free rate (for an equity settlement) or the effective discount rate (for a redemption or cash settlement). The Company also recorded a final adjustment to the Convertible Debentures based on their fair value on the Conversion Date, just prior to the forced conversion being completed. Given that the Company’s prior simulation model included the assumption that the Company would elect to force conversion in 100% of scenarios when the requirements were met, the final valuation was based on the actual results of the forced conversion. As such, the Company based the final fair value adjustment to the Convertible Debentures just prior to conversion on the number of shares of common stock that were issued to the Investors upon conversion and the fair value of the Company’s common stock as of the Conversion Date. The key inputs to the valuation models that were utilized to estimate the fair value of the Convertible Debentures included: Input December 31, 2019 February 21, 2020 Company’s stock price $ 7.77 $ 11.64 Conversion price 4.00 4.00 Remaining term (years) 1.97 0.00 Equity volatility 49.00 % N/A Risk free rate 1.57 % N/A 1 0.45 % N/A 1 100.00 % 100.00 % 1 100.00 % N/A 1 18.52 % N/A 1 Represents a Level 3 unobservable input, as defined in Note 8 - Fair Value Measurements, below. The Company’s stock price was based on the closing stock price on the valuation date. The conversion price was based on the contractual conversion price included in the SPA. The remaining term was determined based on the remaining time period to maturity of the Convertible Debentures, or remaining term under the expectation of the Company’s election of its forced conversion right. The Company’s equity volatility estimate was based on the Company’s historical equity volatility, the Company’s implied and observed volatility of option pricing, and the historical equity and observed volatility of option pricing for a selection of public companies. The risk-free rate was determined based on U.S. Treasury securities with similar terms. The probability of the occurrence of a default event was based on Bloomberg’s 1-year The utilization of the forced conversion right and the default redemption right was based on management’s best estimate of both features being exercised upon the occurrence of the related contingent events. The effective discount rate utilized at the December 31, 2019 valuation date was based on yields on CCC-rated The fair value and principal value of the Convertible Debentures as of December 31, 2019 and the Conversion Date was as follows (in thousands): Convertible Debentures December 31, 2019 February 21, 2020 Fair value, in accordance with fair value option $ 13,642 $ 21,164 Principal value outstanding $ 6,970 $ 6,970 In February 2020 the Company recorded a loss from the change in fair value of the Convertible Debentures of approximately $7.5 million for period through the Conversion Date which is described in the additional fair value disclosures related to the Convertible Debentures in Note 8. Upon the consummation of the forced conversion, the Company issued 1,816,466 shares of common stock with a fair value of approximately $21.2 million, which was reclassified to stockholders’ equity. (d) Principal and Interest Payments Related to Financing Arrangements The Company no longer has any financing agreements as of June 30, 2021. The following amounts are included in interest expense in the Company’s consolidated statement of operations for the three and six months ended June 30, 2021 and 2020 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Cash interest expense $ 26 $ 95 $ 118 $ 138 Interest on convertible debentures — — — 49 Accrual of notes payable final payment 2 8 9 39 Amortization of debt costs — 12 13 19 Total interest expense $ 28 $ 115 $ 140 $ 245

Leases Commitments

Leases Commitments	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Lease Commitments	Note 5 – Lease Commitments Under ASC 842, “Leases” (“ASC 842”), the Company determines if an arrangement contains a lease at inception. A lease is a contract, or part of a contract, that conveys the right to control the use of identified property, plant or equipment (i.e., an identified asset) for a period of time in exchange for consideration. Leases are classified as either operating leases or financing leases. At lease inception, the Company recognizes a lease liability equal to the present value of the remaining lease payments, and a right of use asset equal to the lease liability, subject to certain adjustments, such as for lease incentives. The Company uses its incremental borrowing rate to determine the present value of the lease payments. The Company determines the incremental borrowing rates for its leases by applying its applicable, fully collateralized borrowing rate, with adjustment as appropriate for the lease term. The lease term at the lease commencement date is determined based on the non-cancellable Right-of-use non-lease non-lease ASC 842 includes a number of reassessment and re-measurement re-measurement right-of-use Certain of the Company’s leases include variable lease costs to reimburse the lessor for real estate tax and insurance expenses, and certain non-lease non-lease Components of Leases: The Company has leases for office space and office equipment. The leases have remaining lease terms ranging from less than one year to two years and nine months as of June 30, 2021. The components of lease expense for the three and six months ended June 30, 2021 are as follows (in thousands): Three Months Six Months Ended June 30, Ended June 30, Lease Cost Classification 2021 2021 Operating lease cost - Right of Use Asset Operating expenses $ 217 $ 434 Operating lease cost - Variable Operating expenses 7 $ 64 Total $ 224 $ 498 Other information related to leases was as follows (in thousands): Three Months Six Months Ended June 30, Ended June 30, 2021 2021 Cash paid from operating cash flows for operating leases $ 233 $ 351 As of June 30, 2021 Weighted-average remaining lease term of operating leases 1.72 Weighted-average discount rate for operating leases 5.6 % Maturity of the Company’s lease liabilities as of June 30, 2021 was as follows (in thousands): As of June 30, 2021: Operating 2021 459 2022 899 2023 211 2024 5 Total lease payments 1,574 Less: imputed interest (77 ) Total lease liabilities 1,497 Less: current portion of lease liabilities (851 ) Long-term lease liabilities $ 646

Stockholders Equity

Stockholders Equity	6 Months Ended
	Jun. 30, 2021
Federal Home Loan Banks [Abstract]
Stockholders Equity	Note 6 – Stockholders Equity (a) Financing Activity On March 2, 2021, the Company entered into an underwriting agreement with Guggenheim Securities, LLC, as representative of the several underwriters thereto, in connection with an underwritten public offering of shares of the Company’s common stock at an offering price of $ per share. The offering closed on March 5, 2021 for gross proceeds of approximately $ million and net proceeds of approximately $ million to the Company. (b) Stock-Based Compensation The Company granted options to purchase 0 and 428,938 shares of the Company’s stock during the three and six months ended June 30, 2021 respectively. The full amount of options were granted in the first quarter of 2021. Options granted unde r Company’s stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Average risk-free interest rate N/A 0.26% 0.20% 0.79% Expected dividend yield None None None None Expected life 3.5 years 3.5 years 3.5 years 3.5 years Expected volatility N/A 64.0% to 65.7% 66.0% to 66.0% 50.2 to 65.7% Weighted average exercise price N/A $10.76 $18.00 $10.11 Weighted average fair value N/A $4.96 $8.37 $4.34 Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Cost of revenue $ 2 $ 24 $ 16 $ 24 Engineering and product development 58 288 208 343 Marketing and sales 128 490 481 548 General and administrative 323 811 741 1,162 $ 511 $ 1,613 $ 1,446 $ 2,077 As of June 30, 2021, unrecognized compensation cost (in thousands) related to unvested options and unvested restricted stock and the weighted average term of such equity instruments is as follows: Remaining expense $ 3,113 Weighted average term 1.2 The Company’s restricted stock awards typically vest in either one year or three equal annual installments with the first installment vesting one year from the grant date. The Company did not grant any shares of restricted stock during the three-months ended June 30, 2021 or 2020. The Company shares of restricted stock during the six-months ended June 30, 2021 and 2020, respectively. The Company’s aggregate intrinsic value for stock options and restricted stock outstanding is as follows (in thousands): As of June 30, Aggregate intrinsic value 2021 2020 Stock options $ 20,324 $ 8,992 Restricted stock 374 709 The Company issued 34,814 and 83,748 shares of common stock upon the exercise of outstanding stock options in the three and - Employee Stock Purchase Plan In December 2019, the 2019 Employee Stock Purchase Plan (“ESPP”) was adopted by the Company’s Board of Directors (the “Board”) and approved by stockholders, effective January 1, 2020. The ESPP provides for the issuance of up to 950,000 shares of common stock, subject to adjustment in the event of a stock split, stock dividend or other change in the Company’s capitalization. The ESPP may be terminated or amended by the Board at any time. Certain amendments to the ESPP require stockholder approval. Substantially all of the Company’s employees whose customary employment is for more than 20 hours a week are eligible to participate in the ESPP. Any employee who owns 5% or more of the voting power or value of the Company’s shares of common stock is not eligible to participate in the ESPP. Any eligible employee can enroll in the ESPP as of the beginning of a respective quarterly accumulation period. Employees who participate in the ESPP may purchase shares by authorizing payroll deductions of up to 15% of their base compensation during an accumulation period. Unless the participating employee withdraws from participation, accumulated payroll deductions are used to purchase shares of common stock on the last business day of the accumulation period (the “Purchase Date”) at a price equal to 85% of the lower of the fair market value on (i) the Purchase Date or (ii) the first day of such accumulation period. Under applicable tax rules, no employee may purchase more than $25,000 worth of common stock, valued at the start of the purchase period, under the ESPP in any calendar year. The Company issued 5,890 and 12,212 shares under the ESPP in the three and six-months six-months

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 – Commitments and Contingencies Other Commitments The Company is obligated to pay approximately $4.0 million for firm purchase obligations to suppliers for future product and service deliverables and $0.5 million for minimum royalty obligations. Litigation In December 2016, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Invivo Corporation (“Invivo”). In accordance with the Asset Purchase Agreement, the Company sold to Invivo all right, title and interest to certain intellectual property relating to the Company’s VersaVue Software and DynaCAD product and related assets for $3.2 million. The Company closed the transaction on January 30, 2017 less a holdback reserve of $350,000 (the “Escrowed Amount”) for net proceeds of approximately $2.9 million. On September 5, 2018, third-party Yeda Research and Development Company Ltd. (“Yeda”), filed a complaint (the “Complaint”) against the Company and Invivo in the United States District Court for the Southern District of New York, captioned Yeda Research and Development Company Ltd. v. iCAD, Inc. and Invivo Corporation, Case No. 1:18-cv-08083-GBD, one-time non-conditional of the Escrowed Amount and the Company expensed approximately $93,000 in the three-months ended June 30, 2021. The Company may be a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it the ultimate resolution of which would have a material adverse effect on its financial condition or results of operations. However, should the Company fail to prevail in any legal matter or should several legal matters be resolved against the Company in the same reporting period, such matters could have a material adverse effect on the Company’s operating results and cash flows for that particular period. The Company may be a party to certain actions that have been filed against the Company which are being vigorously defended. The Company has determined that potential losses in these matters are neither probable or reasonably possible at this time. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, “Contingencies.” Legal costs are expensed as incurred.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 8 - Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset • Level 1 - Quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and notes payable and convertible debentures. Due to their short-term nature and market rates of interest, the carrying amounts of the financial instruments (except the Convertible Debentures, which were measured at fair value in accordance with the fair value option election) approximated fair value as of February 21, 2020 and December 31, 2019. The Company’s assets and liabilities that are measured at fair value on a recurring basis include the Company’s money market accounts and Convertible Debentures. The money market accounts are included in cash and cash equivalents in the accompanying consolidated balance sheet and are considered a Level 1 measurement as they are valued at quoted market prices in active markets. The Convertible Debentures were recorded as a separate component of the Company’s consolidated balance sheet and are considered a Level 3 measurement due to the utilization of significant unobservable inputs in their valuation. See Note 4(b) for a discussion of these fair value measurements. The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands). Fair Value Measurements as of December 31, 2020 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 27,186 — — $ 27,186 Total Assets $ 27,186 — — $ 27,186 Fair Value Measurements (in thousands) as of June 30, 2021 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 37,889 — — $ 37,889 Total Assets $ 37,889 — — $ 37,889

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 9 - Income Taxes The Coronavirus Aid, Relief, and Economic Security Act was enacted on March 27, 2020 and did not have a material impact on the Company’s provision for income taxes for the three and six months ended June 30, 2021. The Company recorded an income tax provision of $ for the three and six months ended June 30, 2021, and $5,000 and $ for the three and six months ended June 30, 2020. The Company adopted ASU 2019-12 as of January 1, 2021, in accordance with this provision non-income and state franchise taxes are now classified as a component of operating expenses in General and Administrative expense. Income based tax expense will continue to be recognized as tax expense in the Consolidated Financial Statements. Tax expense for three and six months ended June 30, 2020 represent non-income and state franchise tax, however the expense was not reclassified to operating expenses in accordance with ASU 2019-12. The Company had material unrecognized tax benefits and a deferred tax liability of approximately $ related to tax amortizable goodwill. No other adjustments were required under ASC 740, “Income Taxes.” The Company does not expect that its unrecognized tax benefits will materially increase within the next 12 months. The Company did not recognize any interest or penalties related to uncertain tax positions at June 30, 2021. The Company files United States federal income tax returns and income tax returns in various states and local jurisdictions. The Company’s three preceding tax years remain subject to examination by federal and state tax authorities. In addition, because the Company has net operating loss carry-forwards, the Internal Revenue Service and state jurisdictions are permitted to audit earlier years and propose adjustments up to the amount of net operating loss generated in those years. The Company is not currently under examination by any federal or state jurisdiction for any tax years.

Goodwill

Goodwill	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Note 10 - Goodwill The Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of the reporting unit is less than its carrying value. There were no impairment indicators present as of June 30, 2021. Factors the Company considers important, which could trigger an impairment of such asset, include the following: • significant underperformance relative to historical or projected future operating results; • significant changes in the manner or use of the assets or the strategy for the Company’s overall business; • significant negative industry or economic trends; • significant decline in the Company’s stock price for a sustained period; and • a decline in the Company’s market capitalization below net book value. The Company would record an impairment charge when such assessment indicates that the fair value of a reporting unit is less than the carrying value. In evaluating potential impairments outside of the annual measurement date, judgment is required in determining whether an event has occurred that may impair the value of goodwill or intangible assets. The Company utilizes either discounted cash flow models or other valuation models, such as comparative transactions and market multiples, to determine the fair value of reporting units. The Company makes assumptions about future cash flows, future operating plans, discount rates, comparable companies, market multiples, purchase price premiums and other factors in those models. Different assumptions and judgment determinations could yield different conclusions that would result in an impairment charge to income in the period that such change or determination was made. The Company determines the fair values for each reporting unit using a weighting of the income approach and the market approach. For purposes of the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. The Company uses internal forecasts to estimate future cash flows and includes estimates of long-term future growth rates based on its most recent views of the long-term forecast for each segment. Accordingly, actual results can differ from those assumed in the Company’s forecasts. Discount rates are derived from a capital asset pricing model and by analyzing published rates for industries relevant to the Company’s reporting units to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses of its reporting units and in the Company’s internally developed forecasts. In the market approach, the Company uses a valuation technique in which values are derived based on market prices of publicly traded companies with similar operating characteristics and in similar industries. A market approach allows for comparison to actual market transactions and multiples. It can be somewhat limited in its application because the population of potential comparable publicly-traded companies can be limited due to differing characteristics of the comparative business and the Company, as well as the fact that market data may not be available for divisions within larger conglomerates or non-public The Company corroborates the total fair values of the reporting units using a market capitalization approach; however, this approach cannot be used to determine the fair value of each reporting unit. The blend of the income approach and market approach is more closely aligned to the business profile of the Company, including markets served and products available. In addition, required rates of return, along with uncertainties inherent in the forecast of future cash flows, are reflected in the selection of the discount rate. In addition, under the blended approach, reasonably likely scenarios and associated sensitivities can be developed for alternative future states that may not be reflected in an observable market price. The Company will assess each valuation methodology based upon the relevance and availability of the data at the time the valuation is performed and weights the methodologies appropriately. The Company has two operating segments, Detection and Therapy, as further discussed in Note 12 below. A rollforward of goodwill activity by reportable segment is as follows (in thousands): Consolidated Detection Therapy Total Accumulated Goodwill $ 47,937 $ — $ — $ 47,937 Accumulated impairment (26,828 ) — — (26,828 ) Fair value allocation (21,109 ) 7,663 13,446 — Acquisition of DermEbx and Radion — — 6,154 6,154 Acquisition measurement period adjustments — — 116 116 Acquisition of VuComp — 1,093 — 1,093 Sale of MRI assets — (394 ) (394 ) Impairment — — (19,716 ) (19,716 ) Balance at December 31, 2020 and June 30, 2021 — 8,362 — 8,362

Long-lived assets

Long-lived assets	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Long-lived assets	Note 11 – Long-lived assets The Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than its carrying value. There is no set interval or frequency for recoverability evaluation. Rather, the determination of when, if at all, an asset (or asset group) is evaluated for recoverability is based on “events and circumstances.” The following factors are examples of events or changes in circumstances that indicate the carrying amount of an asset (or asset group) may not be recoverable and thus is to be evaluated for recoverability. • A significant decrease in the market price of a long-lived asset (or asset group); • A significant adverse change in the extent or manner in which a long-lived asset (or asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (or asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (or asset group); and • A current operating period, or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (or asset group). The Company determined there were no such triggering events in the quarter ended June 30, 2021. If the carrying amount of an asset or asset group (in use or under development) is evaluated and found not to be fully recoverable (e.g., the carrying amount exceeds the estimated gross, undiscounted cash flows from use and disposition), then an impairment loss must be recognized. The impairment loss is measured as the excess of the carrying amount over the fair value of the asset (or asset group). The Company determined the “Asset Group” of the Company to be the assets of the Therapy segment and the Detection segment, which the Company considers to be the lowest level for which the identifiable cash flows were largely independent of the cash flows of other assets and liabilities. A considerable amount of judgment and assumptions are required in performing the impairment tests, principally in determining the fair value of the asset group and the reporting unit. While the Company believes that its judgments and assumptions are reasonable, different assumptions could change the estimated fair values and, therefore additional impairment charges could be required. Significant negative industry or economic trends, disruptions to the Company’s business, loss of significant customers, inability to effectively integrate acquired businesses, unexpected significant changes or planned changes in use of the assets may adversely impact the assumptions used in the fair value estimates and ultimately result in future impairment charges.

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Segment Reporting	Note 12 – Segment Reporting Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and assess performance. The Company’s CODM is the Chief Executive Officer. Each reportable segment generates revenue from the sale of medical equipment and related services and/or sale of supplies. The Company has determined there are two segments, Detection and Therapy. The Detection segment consists of the Company’s advanced image analysis and workflow products, and the Therapy segment consists of the Company’s radiation therapy products, “Axxent,” and related services. The primary factors used by the Company’s CODM to allocate resources are based on revenues, gross profit, operating income, and earnings or loss before interest, taxes, depreciation, amortization, and other specific and non-recurring The Company does not track assets by operating segment and the Company’s CODM does not use asset information by segment to allocate resources or make operating decisions. Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to US GAAP loss before income tax is as follows (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Segment revenues: Detection $ 4,789 $ 4,117 $ 10,508 $ 8,593 Therapy 3,037 1,450 5,962 3,525 Total Revenue $ 7,826 $ 5,567 $ 16,470 $ 12,118 Segment gross profit: Detection $ 4,005 $ 3,533 $ 8,730 $ 7,000 Therapy 1,533 824 3,097 1,867 Segment gross profit $ 5,538 $ 4,357 $ 11,827 $ 8,867 Segment operating income (loss): Detection $ 52 $ 201 $ 993 $ (145 ) Therapy (250 ) (432 ) (562 ) (1,438 ) Segment operating income (loss) $ (198 ) $ (231 ) $ 431 $ (1,583 ) General, administrative, depreciation and amortization expense $ (2,673 ) $ (2,080 ) $ (4,835 ) $ (4,621 ) Interest expense (28 ) (115 ) (140 ) (245 ) Other income 5 33 7 75 Loss on extinguishment of debt (386 ) — (386 ) (341 ) Fair value of convertible debentures — — — (7,464 ) Loss before income tax $ (3,280 ) $ (2,393 ) $ (4,923 ) $ (14,179 )

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2021
Text Block [Abstract]
Recent Accounting Pronouncements	Note 13 - Recent Accounting Pronouncements Recently Adopted Accounting Standards In December 2019, the Financial Accounting Standard Board (the “FASB”) issued ASU 2019-12, 2019-12”). 2019-12 2019-12 2019-12 non-income Recently Issued Accounting Standards Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, “Financial (“ASU 2016-13”), ASU 2016-13 2016-13 2016-13 2016-13 In March 2020, the FASB issued ASU 2020-04, 2020-04”). ASU 2020-04 2020-04 2020-04 In August 2020, the FASB issued ASU 2020-06, 470-20) 815-40): 2020-06”). 2020-06 2020-06 2020-06 2020-06 2020-06

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 14 – Subsequent Events The Company held its 2021 annual meeting of stockholders on July 15, 2021 (the “Meeting”). The Company’s stockholders approved all matters submitted by the Company to the stockholders for approval at the Meeting (the “Proposals”), including a proposal to approve and adopt an amendment to the Certificate of Incorporation (the “Amendment to the Certificate of Incorporation”) to increase the Company’s authorized shares of common stock from 30,000,000 shares to 60,000,000 shares, and a proposal to approve an amendment to the Company’s 2016 Stock Incentive Plan, as amended, to increase the number of shares of common stock available thereunder from 2,600,000 shares to 4,700,000 shares and to increase the aggregate number of incentive stock options available thereunder from 1,000,000 to 2,000,000 (the “Plan Amendment”). Following stockholder approval of all Proposals at the Meeting, the Company filed the Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware on July 21, 2021, and the Plan Amendment was made effective as of July 15, 2021.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements of iCAD, Inc. and its subsidiaries (together “iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of the Company’s management, these unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at June 30, 2021, the results of operations of the Company for the three and six-months six-months six-months Although the Company believes that the disclosures made in these interim financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The accompanying interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K six-months
Segments	Segments The Company reports the results of two segments: Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of advanced image analysis and workflow products. The Therapy segment consists of radiation therapy (“Axxent”) products.
Risk and Uncertainty	Risk and Uncertainty On March 12, 2020, the World Health Organization declared COVID-19 COVID-19 COVID-19. stay-at-home COVID-19 It is currently not possible to predict the duration of the pandemic or the time needed for economic activity to return to prior levels. The COVID-19 COVID-19 COVID-19 The Company’s results for the quarter ending June 30, 2021 reflect a negative impact from the COVID-19 COVID-19. COVID-19 Although the Company did not experience any material impact to trade accounts receivable losses in the quarter ended June 30, 2021, the Company’s exposure may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 COVID-19
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements There are no significant recently adopted accounting pronouncements. For a full list of the Company’s response to all relevant recent accounting pronouncements, please refer to Note 13 below.
Revenue Recognition	Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration which the Company expects to be entitled to receive in exchange for these goods or services and excludes any sales incentives or taxes collected from customers which are subsequently remitted to government authorities. Disaggregation of Revenue The following tables presents the Company’s revenues disaggregated by major good or service line, timing of revenue recognition, and sales channel, reconciled to its reportable segments (in thousands). Three months ended June 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 3,164 $ 2,119 $ 5,283 Service contracts 1,625 371 1,996 Supply and source usage agreements — 529 529 Professional services — 18 18 Other — — — $ 4,789 $ 3,037 $ 7,826 Timing of Revenue Recognition Goods transferred at a point in time $ 3,164 $ 2,136 $ 5,300 Services transferred over time 1,625 901 2,526 $ 4,789 $ 3,037 $ 7,826 Sales Channels Direct sales force $ 3,188 $ 1,252 $ 4,440 OEM partners 1,601 — 1,601 Channel partners — 1,785 1,785 $ 4,789 $ 3,037 $ 7,826 Six months ended June 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 7,325 $ 4,222 $ 11,547 Service contracts 3,183 711 3,894 Supply and source usage agreements — 1,010 1,010 Professional services — 19 19 Other — — — $ 10,508 $ 5,962 $ 16,470 Timing of Revenue Recognition Goods transferred at a point in time $ 7,325 $ 4,240 $ 11,565 Services transferred over time 3,183 1,722 4,905 $ 10,508 $ 5,962 $ 16,470 Sales Channels Direct sales force $ 7,063 $ 1,926 $ 8,989 OEM partners 3,445 — 3,445 Channel partners — 4,036 4,036 $ 10,508 $ 5,962 $ 16,470 Three months ended June 30, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 2,702 $ 575 $ 3,277 Service contracts 1,403 385 1,788 Supply and source usage agreements — 490 490 Professional services — — — Other 12 — 12 $ 4,117 $ 1,450 $ 5,567 Timing of Revenue Recognition Goods transferred at a point in time $ 2,714 $ 605 $ 3,319 Services transferred over time 1,403 845 2,248 $ 4,117 $ 1,450 $ 5,567 Sales Channels Direct sales force $ 2,709 $ 805 $ 3,514 OEM partners 1,408 — 1,408 Channel partners — 645 645 $ 4,117 $ 1,450 $ 5,567 Six months ended June 30, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 5,802 $ 1,921 $ 7,723 Service contracts 2,750 732 3,482 Supply and source usage agreements — 861 861 Professional services — 11 11 Other 41 — 41 $ 8,593 $ 3,525 $ 12,118 Timing of Revenue Recognition Goods transferred at a point in time $ 5,843 $ 1,988 $ 7,831 Services transferred over time 2,750 1,537 4,287 $ 8,593 $ 3,525 $ 12,118 Sales Channels Direct sales force $ 4,881 $ 2,274 $ 7,155 OEM partners 3,712 — 3,712 Channel partners — 1,251 1,251 $ 8,593 $ 3,525 $ 12,118 Products. Service Contracts. non-lease Supply and Source Usage Agreements. These agreements represent a separate performance obligation of the Company. The Company allocates revenue to each performance obligation based on the SSP. Professional Services. Other. Contract Balances Contract liabilities are a component of deferred revenue, current contract assets are a component of prepaid and other assets and non-current non-current Contract balances Contract balances Balance at Balance at June 30, 2021 December 31, 2020 Receivables, which are included in ‘Trade accounts receivable’ $ 11,107 $ 10,027 Current contract assets, which are included in “Prepaid and other assets” 742 481 Non-current 1,478 1,434 Contract liabilities, which are included in “Deferred revenue” 6,388 6,384 Timing of revenue recognition may differ from timing of invoicing of customers. The Company records a receivable when revenue is recognized prior to receipt of cash payment and the Company has the unconditional right to such consideration, or unearned revenue when cash payments are received or due in advance of performance. For multi-year agreements, the Company generally invoices customers annually at the beginning of each annual service period. The Company’s accounts receivable from contracts with customers, net of allowance for doubtful accounts, was $ million and $ million as of June 30, 2021 and December 31, 2020, respectively. The Company records net contract assets or contract liabilities on a contract-by-contract non-current non-current Contract liabilities, or deferred revenue from contracts with customers, is primarily composed of fees related to long-term service arrangements, which are generally invoiced in advance. Deferred revenue also includes payments for installation and training that has not yet been completed and other offerings for which the Company has been paid in advance and earn the revenue when it transfers control of the product or service. The balance of deferred revenue at June 30, 2021 and December 31, 2020 was as follows (in thousands): Contract liabilities June 30, 2021 December 31, 2020 Short term $ 5,964 $ 6,117 Long term 424 267 Total $ 6,388 $ 6,384 Changes in deferred revenue from contracts with customers were as follows (in thousands): Six Months Ended June 30, 2021 Balance at beginning of period $ 6,384 Deferral of revenue 6,393 Recognition of deferred revenue (6,389 ) Balance at end of period $ 6,388 The Company expects to recognize estimated revenues related to performance obligation that are unsatisfied (or partially satisfied) in the amounts of approximately $3.8 million in 2021, $3.0 million in 2022, and $1.2 million each year from 2023 through 2025.

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2021
Revenues Disaggregated by Major Good or Service Line, Timing of Revenue Recognition, and Sales Channel, Reconciled to Our Reportable Segments	The following tables presents the Company’s revenues disaggregated by major good or service line, timing of revenue recognition, and sales channel, reconciled to its reportable segments (in thousands). Three months ended June 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 3,164 $ 2,119 $ 5,283 Service contracts 1,625 371 1,996 Supply and source usage agreements — 529 529 Professional services — 18 18 Other — — — $ 4,789 $ 3,037 $ 7,826 Timing of Revenue Recognition Goods transferred at a point in time $ 3,164 $ 2,136 $ 5,300 Services transferred over time 1,625 901 2,526 $ 4,789 $ 3,037 $ 7,826 Sales Channels Direct sales force $ 3,188 $ 1,252 $ 4,440 OEM partners 1,601 — 1,601 Channel partners — 1,785 1,785 $ 4,789 $ 3,037 $ 7,826 Six months ended June 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 7,325 $ 4,222 $ 11,547 Service contracts 3,183 711 3,894 Supply and source usage agreements — 1,010 1,010 Professional services — 19 19 Other — — — $ 10,508 $ 5,962 $ 16,470 Timing of Revenue Recognition Goods transferred at a point in time $ 7,325 $ 4,240 $ 11,565 Services transferred over time 3,183 1,722 4,905 $ 10,508 $ 5,962 $ 16,470 Sales Channels Direct sales force $ 7,063 $ 1,926 $ 8,989 OEM partners 3,445 — 3,445 Channel partners — 4,036 4,036 $ 10,508 $ 5,962 $ 16,470 Three months ended June 30, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 2,702 $ 575 $ 3,277 Service contracts 1,403 385 1,788 Supply and source usage agreements — 490 490 Professional services — — — Other 12 — 12 $ 4,117 $ 1,450 $ 5,567 Timing of Revenue Recognition Goods transferred at a point in time $ 2,714 $ 605 $ 3,319 Services transferred over time 1,403 845 2,248 $ 4,117 $ 1,450 $ 5,567 Sales Channels Direct sales force $ 2,709 $ 805 $ 3,514 OEM partners 1,408 — 1,408 Channel partners — 645 645 $ 4,117 $ 1,450 $ 5,567 Six months ended June 30, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 5,802 $ 1,921 $ 7,723 Service contracts 2,750 732 3,482 Supply and source usage agreements — 861 861 Professional services — 11 11 Other 41 — 41 $ 8,593 $ 3,525 $ 12,118 Timing of Revenue Recognition Goods transferred at a point in time $ 5,843 $ 1,988 $ 7,831 Services transferred over time 2,750 1,537 4,287 $ 8,593 $ 3,525 $ 12,118 Sales Channels Direct sales force $ 4,881 $ 2,274 $ 7,155 OEM partners 3,712 — 3,712 Channel partners — 1,251 1,251 $ 8,593 $ 3,525 $ 12,118
Summary of Receivables, Contract Assets and Contract Liabilities from Contracts with Customers	The following table provides information about receivables, current and non-current Contract balances Contract balances Balance at Balance at June 30, 2021 December 31, 2020 Receivables, which are included in ‘Trade accounts receivable’ $ 11,107 $ 10,027 Current contract assets, which are included in “Prepaid and other assets” 742 481 Non-current 1,478 1,434 Contract liabilities, which are included in “Deferred revenue” 6,388 6,384
Summary of Changes in Deferred Revenue	Changes in deferred revenue from contracts with customers were as follows (in thousands): Six Months Ended June 30, 2021 Balance at beginning of period $ 6,384 Deferral of revenue 6,393 Recognition of deferred revenue (6,389 ) Balance at end of period $ 6,388
Accounting Standards Update 2016-02 [Member]
Summary of Changes in Deferred Revenue	Contract liabilities June 30, 2021 December 31, 2020 Short term $ 5,964 $ 6,117 Long term 424 267 Total $ 6,388 $ 6,384

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Calculation of Net Loss Per Share	A summary of the Company’s calculation of net loss per share is as follows (in thousands except per share amounts): Three Months Ended Six Months Ended 2021 2020 2021 2020 Net loss $ (3,280 ) $ (2,398 ) $ (4,923 ) $ (14,210 ) Shares used in the calculation of basic and diluted net loss per share 24,989 22,396 24,462 21,275 Diluted shares used in the calculation of net loss per share 24,989 22,396 24,462 21,275 Net loss per share - basic and diluted $ (0.13 ) $ (0.11 ) $ (0.20 ) $ (0.67 )
Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share	The shares of the Company’s common stock issuable upon the exercise of convertible securities, stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive are as follows: As of June 30, 2021 2020 Stock options 2,176,607 2,006,221 Restricted stock 21,613 70,992 Total 2,198,220 2,077,213

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Schedule of Current Inventory	June 30, 2021 December 31, 2020 Raw materials $ 1,518 $ 1,538 Work in process 192 76 Finished Goods 1,381 1,774 Inventory Gross 3,091 3,388 Inventory Reserve (230 ) (244 ) Inventory Net $ 2,861 $ 3,144

Financing Arrangements (Tables)

Financing Arrangements (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Schedule of Key Inputs to Simulation Model Utilized to Estimate Fair Value of Convertible Debentures	The key inputs to the valuation models that were utilized to estimate the fair value of the Convertible Debentures included: Input December 31, 2019 February 21, 2020 Company’s stock price $ 7.77 $ 11.64 Conversion price 4.00 4.00 Remaining term (years) 1.97 0.00 Equity volatility 49.00 % N/A Risk free rate 1.57 % N/A 1 0.45 % N/A 1 100.00 % 100.00 % 1 100.00 % N/A 1 18.52 % N/A
Schedule of Fair Value and Principal Value of Convertible Debentures	The fair value and principal value of the Convertible Debentures as of December 31, 2019 and the Conversion Date was as follows (in thousands): Convertible Debentures December 31, 2019 February 21, 2020 Fair value, in accordance with fair value option $ 13,642 $ 21,164 Principal value outstanding $ 6,970 $ 6,970
Interest Expense in Consolidated Income Statement	The following amounts are included in interest expense in the Company’s consolidated statement of operations for the three and six months ended June 30, 2021 and 2020 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Cash interest expense $ 26 $ 95 $ 118 $ 138 Interest on convertible debentures — — — 49 Accrual of notes payable final payment 2 8 9 39 Amortization of debt costs — 12 13 19 Total interest expense $ 28 $ 115 $ 140 $ 245

Leases Commitments (Tables)

Leases Commitments (Tables)	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of Components of Lease Expense	The components of lease expense for the three and six months ended June 30, 2021 are as follows (in thousands): Three Months Six Months Ended June 30, Ended June 30, Lease Cost Classification 2021 2021 Operating lease cost - Right of Use Asset Operating expenses $ 217 $ 434 Operating lease cost - Variable Operating expenses 7 $ 64 Total $ 224 $ 498 Other information related to leases was as follows (in thousands): Three Months Six Months Ended June 30, Ended June 30, 2021 2021 Cash paid from operating cash flows for operating leases $ 233 $ 351 As of June 30, 2021 Weighted-average remaining lease term of operating leases 1.72 Weighted-average discount rate for operating leases 5.6 %
Summary of Detained Information of Lease Liabilities	Maturity of the Company’s lease liabilities as of June 30, 2021 was as follows (in thousands): As of June 30, 2021: Operating 2021 459 2022 899 2023 211 2024 5 Total lease payments 1,574 Less: imputed interest (77 ) Total lease liabilities 1,497 Less: current portion of lease liabilities (851 ) Long-term lease liabilities $ 646

Stockholders Equity (Tables)

Stockholders Equity (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values	Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Average risk-free interest rate N/A 0.26% 0.20% 0.79% Expected dividend yield None None None None Expected life 3.5 years 3.5 years 3.5 years 3.5 years Expected volatility N/A 64.0% to 65.7% 66.0% to 66.0% 50.2 to 65.7% Weighted average exercise price N/A $10.76 $18.00 $10.11 Weighted average fair value N/A $4.96 $8.37 $4.34
Stock-Based Compensation Expense Including Options and Restricted Stock by Category	Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Cost of revenue $ 2 $ 24 $ 16 $ 24 Engineering and product development 58 288 208 343 Marketing and sales 128 490 481 548 General and administrative 323 811 741 1,162 $ 511 $ 1,613 $ 1,446 $ 2,077
Unrecognized Compensation Cost Related to Unexercisable Options and Unvested Restricted Stock and Weighted Average Remaining Period	As of June 30, 2021, unrecognized compensation cost (in thousands) related to unvested options and unvested restricted stock and the weighted average term of such equity instruments is as follows: Remaining expense $ 3,113 Weighted average term 1.2
Aggregate Intrinsic Value	The Company’s aggregate intrinsic value for stock options and restricted stock outstanding is as follows (in thousands): As of June 30, Aggregate intrinsic value 2021 2020 Stock options $ 20,324 $ 8,992 Restricted stock 374 709

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Assets and Liabilities which are Measured at Fair Value on a Recurring Basis	The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands). Fair Value Measurements as of December 31, 2020 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 27,186 — — $ 27,186 Total Assets $ 27,186 — — $ 27,186 Fair Value Measurements (in thousands) as of June 30, 2021 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 37,889 — — $ 37,889 Total Assets $ 37,889 — — $ 37,889

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Roll Forward of Goodwill Activity by Reportable Segment	A rollforward of goodwill activity by reportable segment is as follows (in thousands): Consolidated Detection Therapy Total Accumulated Goodwill $ 47,937 $ — $ — $ 47,937 Accumulated impairment (26,828 ) — — (26,828 ) Fair value allocation (21,109 ) 7,663 13,446 — Acquisition of DermEbx and Radion — — 6,154 6,154 Acquisition measurement period adjustments — — 116 116 Acquisition of VuComp — 1,093 — 1,093 Sale of MRI assets — (394 ) (394 ) Impairment — — (19,716 ) (19,716 ) Balance at December 31, 2020 and June 30, 2021 — 8,362 — 8,362

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss	Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to US GAAP loss before income tax is as follows (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Segment revenues: Detection $ 4,789 $ 4,117 $ 10,508 $ 8,593 Therapy 3,037 1,450 5,962 3,525 Total Revenue $ 7,826 $ 5,567 $ 16,470 $ 12,118 Segment gross profit: Detection $ 4,005 $ 3,533 $ 8,730 $ 7,000 Therapy 1,533 824 3,097 1,867 Segment gross profit $ 5,538 $ 4,357 $ 11,827 $ 8,867 Segment operating income (loss): Detection $ 52 $ 201 $ 993 $ (145 ) Therapy (250 ) (432 ) (562 ) (1,438 ) Segment operating income (loss) $ (198 ) $ (231 ) $ 431 $ (1,583 ) General, administrative, depreciation and amortization expense $ (2,673 ) $ (2,080 ) $ (4,835 ) $ (4,621 ) Interest expense (28 ) (115 ) (140 ) (245 ) Other income 5 33 7 75 Loss on extinguishment of debt (386 ) — (386 ) (341 ) Fair value of convertible debentures — — — (7,464 ) Loss before income tax $ (3,280 ) $ (2,393 ) $ (4,923 ) $ (14,179 )

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2021USD ($)Segment	Dec. 31, 2020USD ($)
Basis Of Presentation And Significant Accounting Policies [Line Items]
Business segment | Segment	2
2021 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated revenue remaining performance obligation,amount	$ 3.8
2022 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated revenue remaining performance obligation,amount	3
2023 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated revenue remaining performance obligation,amount	1.2
2024 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated revenue remaining performance obligation,amount	1.2
2025 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated revenue remaining performance obligation,amount	1.2
Revenue from Contract with Customer [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Allowance for doubtful accounts, receivable	$ 11.1	$ 10

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - Revenues Disaggregated by Major Good or Service Line, Timing of Revenue Recognition, and Sales Channel, Reconciled to Our Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	$ 7,826	$ 5,567	$ 16,470	$ 12,118
Products [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	5,283	3,277	11,547	7,723
Service Contracts [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,996	1,788	3,894	3,482
Supply and Source Usage Agreements [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	529	490	1,010	861
Professional Services [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	18		19	11
Other [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers		12		41
Goods Transferred at a Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	5,300	3,319	11,565	7,831
Services Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,526	2,248	4,905	4,287
Direct Sales Force [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	4,440	3,514	8,989	7,155
OEM Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,601	1,408	3,445	3,712
Channel Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,785	645	4,036	1,251
Detection [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	4,789	4,117	10,508	8,593
Detection [Member] | Products [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	3,164	2,702	7,325	5,802
Detection [Member] | Service Contracts [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,625	1,403	3,183	2,750
Detection [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers		12		41
Detection [Member] | Goods Transferred at a Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	3,164	2,714	7,325	5,843
Detection [Member] | Services Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,625	1,403	3,183	2,750
Detection [Member] | Direct Sales Force [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	3,188	2,709	7,063	4,881
Detection [Member] | OEM Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,601	1,408	3,445	3,712
Therapy [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	3,037	1,450	5,962	3,525
Therapy [Member] | Products [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,119	575	4,222	1,921
Therapy [Member] | Service Contracts [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	371	385	711	732
Therapy [Member] | Supply and Source Usage Agreements [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	529	490	1,010	861
Therapy [Member] | Professional Services [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	18		19	11
Therapy [Member] | Goods Transferred at a Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,136	605	4,240	1,988
Therapy [Member] | Services Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	901	845	1,722	1,537
Therapy [Member] | Direct Sales Force [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,252	805	1,926	2,274
Therapy [Member] | Channel Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	$ 1,785	$ 645	$ 4,036	$ 1,251

Basis of Presentation and Sig_6

Basis of Presentation and Significant Accounting Policies - Summary of Receivables, Contract Assets and Contract Liabilities from Contracts with Customers (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Contract with Customer, Asset and Liability [Abstract]
Receivables, which are included in ‘Trade accounts receivable'	$ 11,107	$ 10,027
Current contract assets, which are included in "Prepaid and other assets"	742	481
Non-current contract assets, which are included in "other assets"	1,478	1,434
Contract liabilities, which are included in "Deferred revenue"	$ 6,388	$ 6,384

Basis of Presentation and Sig_7

Basis of Presentation and Significant Accounting Policies - Summary of Deferred Revenue (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Deferred Revenue Arrangement [Line Items]
Contract liabilities	$ 6,388	$ 6,384
Short-term Contract with Customer [Member]
Deferred Revenue Arrangement [Line Items]
Contract liabilities	5,964	6,117
Long-term Contract with Customer [Member]
Deferred Revenue Arrangement [Line Items]
Contract liabilities	$ 424	$ 267

Basis of Presentation and Sig_8

Basis of Presentation and Significant Accounting Policies - Summary of Changes in Deferred Revenue from Contracts with Customers (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Deferred Revenue Disclosure [Abstract]
Balance at beginning of period	$ 6,384
Deferral of revenue	6,393
Recognition of deferred revenue	(6,389)
Balance at end of period	$ 6,388

Net Loss per Common Share - Cal

Net Loss per Common Share - Calculation of Net Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Net loss	$ (3,280)	$ (2,398)	$ (4,923)	$ (14,210)
Shares used in the calculation of basic and diluted net loss per share	24,989	22,396	24,462	21,275
Effect of dilutive securities:
Diluted shares used in the calculation of net loss per share	24,989	22,396	24,462	21,275
Net loss per share - basic and diluted	$ (0.13)	$ (0.11)	$ (0.20)	$ (0.67)

Net Loss per Common Share - Sch

Net Loss per Common Share - Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	2,198,220	2,077,213
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	2,176,607	2,006,221
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	21,613	70,992

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventory reserve	$ 230	$ 244

Inventory - Schedule of Current

Inventory - Schedule of Current Inventory (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 1,518	$ 1,538
Work in process	192	76
Finished Goods	1,381	1,774
Inventory Gross	3,091	3,388
Inventory Reserve	(230)	(244)
Inventory Net	$ 2,861	$ 3,144

Financing Arrangements - Additi

Financing Arrangements - Additional Information (Detail)	Apr. 27, 2021USD ($)	Mar. 30, 2020USD ($)	Feb. 29, 2020USD ($)	Jun. 30, 2021USD ($)$ / shares	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)customerTrial$ / sharesshares	Jun. 30, 2020USD ($)	Feb. 21, 2021USD ($)	Feb. 21, 2020USD ($)	Dec. 31, 2019USD ($)	Aug. 07, 2017USD ($)
Debt Instrument [Line Items]
Line of credit, closing costs				$ 141,000		$ 141,000
Debt insrument redemption description						The simulation utilized the assumptions that if the Company was able to exercise its forced conversion right (if the requirements to do so were met), that it would do so in 100% of such scenarios. Additionally, if an event of default occurred during the simulated trial (based on the Company’s probability of default), the Investors would opt to redeem the Convertible Debentures in 100% of such scenarios.
Loss from fair value of the convertible debentures			$ 7,500,000
Final payment of loan		$ 510,000
Gain (Loss) on Extinguishment of Debt				(386,000)	$ 0	$ (386,000)	$ (341,000)
Reclassified the fair value of convertible debentures								$ 21,200,000	$ 21,164,000	$ 13,642,000
Obligations repaid	$ 7,354,283,000						$ 2,000,000
ICAD Western Alliance Bank [Member]
Debt Instrument [Line Items]
Final payment of loan						122,500,000
Termination Loans				50,000,000		50,000,000
Other Costs						15,000,000
Gain (Loss) on Extinguishment of Debt						386,000,000
ICAD Western Alliance Bank [Member] | Debt Prepayment Cost [Member]
Debt Instrument [Line Items]
Debt prepayment cost						140,000,000
ICAD Western Alliance Bank [Member] | Final Payment Of Loan [Member]
Debt Instrument [Line Items]
Final payment of loan						122,000,000
ICAD Western Alliance Bank [Member] | Termination Loans [Member]
Debt Instrument [Line Items]
Termination Loans				65,000,000		65,000,000
ICAD Western Alliance Bank [Member] | Unamortized Debt Issuance Expense [Member]
Debt Instrument [Line Items]
Unamortized closing costs				58,000,000		58,000,000
Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Termination Loans				$ 114,000		$ 114,000
Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Final payment of loan		185,000
Termination Loans		114,000
Other Costs		10,000
Gain (Loss) on Extinguishment of Debt		341,000
Unamortized closing costs		$ 42,000
Western Alliance Bank [Member]
Debt Instrument [Line Items]
Interest Rate During Period		3.25%
Interest Rate Description						6.0
Western Alliance Bank [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Interest Rate During Period		4.25%
Western Alliance Bank [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Interest Rate During Period		1.00%
Convertible Debt [Member]
Debt Instrument [Line Items]
Aggregate principal amount										$ 7,000,000
Debt conversion, conversion price per share | $ / shares				$ 4		$ 4
Convertible debenture Number of instrumnts converted | customer						1,742,500
Shares issued up on conversion | shares						1,816,466
Convertible Debt [Member] | Make Whole Provision [Member]
Debt Instrument [Line Items]
Aggregate principal amount				$ 697,000		$ 697,000
Convertible debenture Number of instrumnts converted | customer						76,966
Convertible Debt [Member] | Monte Carlo Simulation [Member]
Debt Instrument [Line Items]
Number of trials to detremine fair value | Trial						100,000
Term Loan A [Member] | Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Credit facility		$ 7,000,000
Revolving Credit Facility [Member] | Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Credit facility		$ 5,000,000									$ 4,000,000

Financing Arrangements - Schedu

Financing Arrangements - Schedule of Key Inputs to Simulation Model Utilized to Estimate Fair Value of Convertible Debentures (Detail) - Convertible Debt [Member]		Feb. 21, 2020yr	Dec. 31, 2019yr
Company's Stock Price [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input		11.64	7.77
Conversion Price [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input		4	4
Remaining Term (Years) [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input		0	1.97
Equity Volatility [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input			49
Risk Free Rate [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input			1.57
Probability of Default Event [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input	[1]		0.45
Utilization of Forced Conversion [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input	[1]	100	100
Exercise of Default Redemption [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input	[1]		100
Effective Discount Rate [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input	[1]		18.52
[1]	Represents a Level 3 unobservable input, as defined in Note 8 - Fair Value Measurements, below.

Financing Arrangements - Sche_2

Financing Arrangements - Schedule of Fair Value and Principal Value of Convertible Debentures (Detail) - USD ($) $ in Thousands	Feb. 21, 2021	Feb. 21, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Fair value, in accordance with fair value option	$ 21,200	$ 21,164	$ 13,642
Principal value outstanding		$ 6,970	$ 6,970

Financing Arrangements - Intere

Financing Arrangements - Interest Expense in Consolidated Income Statement (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Interest Expense [Line Items]
Cash interest expense	$ 26	$ 95	$ 118	$ 138
Interest on convertible debentures		0		49
Accrual of notes payable final payment	2	8	9	39
Amortization of debt costs		12	13	19
Total interest expense	$ 28	$ 115	$ 140	$ 245

Leases Commitments - Additional

Leases Commitments - Additional Information (Detail)	9 Months Ended
	Jun. 30, 2021
Maximum [Member]
Lessee, Lease, Description [Line Items]
Remaining lease term	2 years
Minimum [Member]
Lessee, Lease, Description [Line Items]
Remaining lease term	1 year

Leases Commitments - Schedule o

Leases Commitments - Schedule of Components of Lease Expense (Detail) - Accounting Standards Update 2016-02 [Member] $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2021USD ($)
Lessee, Lease, Description [Line Items]
Operating lease cost - Right of Use Asset	$ 217	$ 434
Operating lease cost - Variable	7	64
Finance lease costs
Total	224	498
Cash paid from operating cash flows for operating leases	$ 233	$ 351
Weighted-average remaining lease term of operating leases	1 year 8 months 19 days	1 year 8 months 19 days
Weighted-average discount rate for operating leases	5.60%	5.60%

Leases Commitments - Summary of

Leases Commitments - Summary of Detained Information of Lease Liabilities (Detail) $ in Thousands	Jun. 30, 2021USD ($)
Leases [Abstract]
2021	$ 459
2022	899
2023	211
2024	5
Total	1,574
Less: imputed interest	(77)
Total lease liabilities	1,497
Less: current portion of lease liabilities	(851)
Total lease liabilities	$ 646

Stockholders Equity - Additiona

Stockholders Equity - Additional Information (Detail) - USD ($)	Mar. 02, 2021	Dec. 31, 2019	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Net proceeds from Issue of common stock					$ 23,229,000	$ 12,289,000
Underwritten public offering shares	1,393,738
Offering price, per share	$ 18
Gross proceeds from sale of units	$ 25,100,000
Net proceeds from sale of units	$ 23,200,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option Granted			0	0	22,488	0
Number of shares vested			10,041		30,041
Intrinsic value of restricted shares that vested			$ 200,000		$ 500,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, Issued			34,814		83,748
Net proceeds from Issue of common stock			$ 364,000,000		$ 636,000,000
2019 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of voting power		5.00%
Description of employee stock purchase plan					Employees who participate in the ESPP may purchase shares by authorizing payroll deductions of up to 15% of their base compensation during an accumulation period. Unless the participating employee withdraws from participation, accumulated payroll deductions are used to purchase shares of common stock on the last business day of the accumulation period (the “Purchase Date”) at a price equal to 85% of the lower of the fair market value on (i) the Purchase Date or (ii) the first day of such accumulation period. Under applicable tax rules, no employee may purchase more than $25,000 worth of common stock, valued at the start of the purchase period, under the ESPP in any calendar year.
Number of shares issued, Employee Stock Purchase Plans		950,000	5,890		12,212
Stock-based compensation expense			$ 26,000		$ 53,000
Employee-related Liabilities, Current			$ 79,000		$ 79,000
Black Scholes Model [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option Granted			0		428,938

Stockholders Equity - Options G

Stockholders Equity - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Detail) - Stock Options [Member] - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average risk-free interest rate		0.26%	0.20%	0.79%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Expected life	3 years 6 months	3 years 6 months	3 years 6 months	3 years 6 months
Weighted average exercise price		$ 10.76	$ 18	$ 10.11
Weighted average fair value		$ 4.96	$ 8.37	$ 4.34
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility		64.00%	66.00%	50.20%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility		65.70%	66.00%	65.70%

Stockholders Equity - Stock-Bas

Stockholders Equity - Stock-Based Compensation Expense Including Options and Restricted Stock by Category (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 511	$ 1,613	$ 1,446	$ 2,077
Cost of Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	2	24	16	24
Engineering and Product Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	58	288	208	343
Marketing and Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	128	490	481	548
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 323	$ 811	$ 741	$ 1,162

Stockholders Equity - Unrecogni

Stockholders Equity - Unrecognized Compensation Cost Related to Unexercisable Options and Unvested Restricted Stock and Weighted Average Remaining Period (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract]
Remaining expense	$ 3,113
Weighted average term	1 year 2 months 12 days

Stockholders Equity - Aggregate

Stockholders Equity - Aggregate Intrinsic Value (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option	$ 20,324	$ 8,992
Restricted stock	$ 374	$ 709

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	Apr. 13, 2021	Jun. 30, 2021	Jun. 30, 2017	Dec. 31, 2016
Schedule Of Leases [Line Items]
Purchase obligations to suppliers for future product deliverables		$ 4,000
Minimum royalty obligations		500
Cash paid on litigation	$ 85,000
Escrowed amount payable by other party		50,000
Litigation Settlement, Expense		$ 93,000
VersaVue Software and DynaCAD Product and Related Assets [Member] | Asset Purchase Agreement [Member]
Schedule Of Leases [Line Items]
Sale and transfer of intangible assets				$ 3,200
Holdback reserve related to sale and transfer of intangible assets			$ 350,000
Proceeds from sale and transfer of intangible assets			$ 2,900

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities which are Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Assets
Total Assets	$ 37,889	$ 27,186
Money Market Accounts [Member]
Assets
Total Assets	37,889	27,186
Level 1 [Member]
Assets
Total Assets	37,889	27,186
Level 1 [Member] | Money Market Accounts [Member]
Assets
Total Assets	$ 37,889	$ 27,186

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Schedule Of Income Tax Expense [Line Items]
Unrecognized tax benefits	$ 0		$ 0
Deferred Tax Liabilities, Goodwill	4,000		4,000
Income tax provision	$ 0	$ 5,000	$ 0	$ 31,000

Goodwill - Additional Informati

Goodwill - Additional Information (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill Impairment	$ 0

Goodwill - Roll Forward of Good

Goodwill - Roll Forward of Goodwill Activity by Reportable Segment (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Accumulated Goodwill	$ 47,937
Accumulated impairment	(26,828)
Acquisition measurement period adjustments	116
Sale of MRI assets	(394)
Impairment	(19,716)
Goodwill, Ending Balance	8,362	$ 8,362
DermEbx And Radion [Member]
Acquisition cost	6,154
VuComp M-Vu Breast Density Product [Member]
Acquisition cost	1,093
Consolidated Reporting Unit [Member]
Accumulated Goodwill	47,937
Accumulated impairment	(26,828)
Fair value allocation	(21,109)
Detection [Member]
Fair value allocation	7,663
Sale of MRI assets	(394)
Goodwill, Ending Balance	8,362	$ 8,362
Detection [Member] | VuComp M-Vu Breast Density Product [Member]
Acquisition cost	1,093
Therapy [Member]
Fair value allocation	13,446
Acquisition measurement period adjustments	116
Impairment	(19,716)
Therapy [Member] | DermEbx And Radion [Member]
Acquisition cost	$ 6,154

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2021Segment
Schedule Of Geographical Information [Line Items]
Number of reporting segments	2

Segment Reporting - Summary of

Segment Reporting - Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Segment revenues:
Total Revenue	$ 7,826	$ 5,567	$ 16,470	$ 12,118
Segment gross profit:
Segment gross profit	5,538	4,357	11,827	8,867
Segment operating income (loss):
Segment operating income (loss)	(198)	(231)	431	(1,583)
General, administrative, depreciation and amortization expense	(2,673)	(2,080)	(4,835)	(4,621)
Interest expense	(28)	(115)	(140)	(245)
Other income	5	33	7	75
Loss on extinguishment of debt	(386)	0	(386)	(341)
Fair value of convertible debentures				(7,464)
Loss before income tax expense	(3,280)	(2,393)	(4,923)	(14,179)
Product [Member]
Segment revenues:
Total Revenue	4,552	2,888	10,109	6,683
Service [Member]
Segment revenues:
Total Revenue	3,274	2,679	6,361	5,435
Detection [Member]
Segment gross profit:
Segment gross profit	4,005	3,533	8,730	7,000
Segment operating income (loss):
Segment operating income (loss)	52	201	993	(145)
Detection [Member] | Product [Member]
Segment revenues:
Total Revenue	4,789	4,117	10,508	8,593
Therapy [Member]
Segment gross profit:
Segment gross profit	1,533	824	3,097	1,867
Segment operating income (loss):
Segment operating income (loss)	(250)	(432)	(562)	(1,438)
Therapy [Member] | Service [Member]
Segment revenues:
Total Revenue	$ 3,037	$ 1,450	$ 5,962	$ 3,525

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member]	Jul. 15, 2021shares
Amendment To 2016 Stock Incentive Plan [Member]
Number of shares of common stock available to issue, Shares	2,600,000
Increase in number of shares of common stock available to issue,Shares	4,700,000
Amendment To Incentive Stock Options [Member]
Number of shares of common stock available to issue, Shares	1,000,000
Increase in number of shares of common stock available to issue,Shares	2,000,000
Amendment To The Certificate Of Incorporation [Member]
Number of authorized shares of common stock,Shares	30,000,000
Increase in number of authorized shares of common stock, Shares	60,000,000